AMNEAL PHARMACEUTICALS INC (AMRX) Fundamental Analysis & Valuation

NASDAQ:AMRX • US03168L1052

Current stock price

12.54 USD
-0.26 (-2.03%)
At close:
12.54 USD
0 (0%)
After Hours:

This AMRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. AMRX Profitability Analysis

1.1 Basic Checks

  • In the past year AMRX was profitable.
  • AMRX had a positive operating cash flow in the past year.
  • In multiple years AMRX reported negative net income over the last 5 years.
  • In the past 5 years AMRX always reported a positive cash flow from operatings.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • AMRX has a Return On Assets of 1.96%. This is amongst the best in the industry. AMRX outperforms 82.38% of its industry peers.
  • With an excellent Return On Invested Capital value of 11.24%, AMRX belongs to the best of the industry, outperforming 90.67% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for AMRX is below the industry average of 13.06%.
  • The 3 year average ROIC (10.04%) for AMRX is below the current ROIC(11.24%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.96%
ROE N/A
ROIC 11.24%
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300 -400

1.3 Margins

  • AMRX has a Profit Margin of 2.39%. This is amongst the best in the industry. AMRX outperforms 80.83% of its industry peers.
  • In the last couple of years the Profit Margin of AMRX has declined.
  • The Operating Margin of AMRX (13.18%) is better than 85.49% of its industry peers.
  • AMRX's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 36.88%, AMRX perfoms like the industry average, outperforming 59.07% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AMRX has grown nicely.
Industry RankSector Rank
OM 13.18%
PM (TTM) 2.39%
GM 36.88%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. AMRX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
  • AMRX has more shares outstanding than it did 1 year ago.
  • AMRX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, AMRX has an improved debt to assets ratio.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • AMRX has an Altman-Z score of 1.95. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • AMRX has a Altman-Z score (1.95) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of AMRX is 11.66, which is on the high side as it means it would take AMRX, 11.66 years of fcf income to pay off all of its debts.
  • AMRX has a Debt to FCF ratio of 11.66. This is in the better half of the industry: AMRX outperforms 78.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.66
Altman-Z 1.95
ROIC/WACC1.19
WACC9.46%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • AMRX has a Current Ratio of 2.17. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
  • AMRX has a Current ratio (2.17) which is in line with its industry peers.
  • A Quick Ratio of 1.48 indicates that AMRX should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.48, AMRX is doing worse than 67.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 1.48
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.83% over the past year.
  • The Earnings Per Share has been growing slightly by 5.92% on average over the past years.
  • Looking at the last year, AMRX shows a quite strong growth in Revenue. The Revenue has grown by 8.05% in the last year.
  • Measured over the past years, AMRX shows a quite strong growth in Revenue. The Revenue has been growing by 8.66% on average per year.
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%

3.2 Future

  • Based on estimates for the next years, AMRX will show a small growth in Earnings Per Share. The EPS will grow by 5.77% on average per year.
  • The Revenue is expected to decrease by -0.47% on average over the next years.
EPS Next Y20.21%
EPS Next 2Y19.5%
EPS Next 3Y18.59%
EPS Next 5Y5.77%
Revenue Next Year2.6%
Revenue Next 2Y4.84%
Revenue Next 3Y5.45%
Revenue Next 5Y-0.47%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

8

4. AMRX Valuation Analysis

4.1 Price/Earnings Ratio

  • AMRX is valuated correctly with a Price/Earnings ratio of 14.93.
  • 86.01% of the companies in the same industry are more expensive than AMRX, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of AMRX to the average of the S&P500 Index (26.78), we can say AMRX is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 12.42 indicates a correct valuation of AMRX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 83.94% of the companies listed in the same industry.
  • AMRX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.54.
Industry RankSector Rank
PE 14.93
Fwd PE 12.42
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 87.56% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, AMRX is valued cheaply inside the industry as 86.01% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.73
EV/EBITDA 10.21
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AMRX has a very decent profitability rating, which may justify a higher PE ratio.
  • AMRX's earnings are expected to grow with 18.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.74
PEG (5Y)2.52
EPS Next 2Y19.5%
EPS Next 3Y18.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMRX Dividend Analysis

5.1 Amount

  • No dividends for AMRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMRX Fundamentals: All Metrics, Ratios and Statistics

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (4/10/2026, 8:06:01 PM)

After market: 12.54 0 (0%)

12.54

-0.26 (-2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)05-01
Inst Owners45.62%
Inst Owner Change0%
Ins Owners43.95%
Ins Owner Change8.28%
Market Cap4.00B
Revenue(TTM)3.02B
Net Income(TTM)72.06M
Analysts81.82
Price Target16.83 (34.21%)
Short Float %7.01%
Short Ratio3.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)11.53%
Max EPS beat(2)21.21%
EPS beat(4)4
Avg EPS beat(4)28.29%
Min EPS beat(4)11.53%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)21.12%
EPS beat(12)11
Avg EPS beat(12)30.53%
EPS beat(16)12
Avg EPS beat(16)21.16%
Revenue beat(2)0
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)-0.41%
Revenue beat(4)0
Avg Revenue beat(4)-2.73%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.24%
Revenue beat(12)6
Avg Revenue beat(12)0.1%
Revenue beat(16)8
Avg Revenue beat(16)-0.09%
PT rev (1m)13.79%
PT rev (3m)17.86%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)-14.47%
EPS NY rev (1m)3.53%
EPS NY rev (3m)6.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.81%
Revenue NY rev (1m)-1%
Revenue NY rev (3m)-3.78%
Valuation
Industry RankSector Rank
PE 14.93
Fwd PE 12.42
P/S 1.33
P/FCF 17.73
P/OCF 11.77
P/B N/A
P/tB N/A
EV/EBITDA 10.21
EPS(TTM)0.84
EY6.7%
EPS(NY)1.01
Fwd EY8.05%
FCF(TTM)0.71
FCFY5.64%
OCF(TTM)1.07
OCFY8.5%
SpS9.46
BVpS-0.22
TBVpS-3.86
PEG (NY)0.74
PEG (5Y)2.52
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.96%
ROE N/A
ROCE 14.23%
ROIC 11.24%
ROICexc 12.5%
ROICexgc 23.19%
OM 13.18%
PM (TTM) 2.39%
GM 36.88%
FCFM 7.47%
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
ROICexc(3y)10.72%
ROICexc(5y)8.59%
ROICexgc(3y)22.54%
ROICexgc(5y)18.52%
ROCE(3y)13.13%
ROCE(5y)10.51%
ROICexgc growth 3Y26.84%
ROICexgc growth 5Y18.51%
ROICexc growth 3Y34.73%
ROICexc growth 5Y26.54%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.66
Debt/EBITDA 4.22
Cap/Depr 51.15%
Cap/Sales 3.79%
Interest Coverage 2.01
Cash Conversion 54.71%
Profit Quality 313.13%
Current Ratio 2.17
Quick Ratio 1.48
Altman-Z 1.95
F-Score7
WACC9.46%
ROIC/WACC1.19
Cap/Depr(3y)37.69%
Cap/Depr(5y)34.67%
Cap/Sales(3y)3.12%
Cap/Sales(5y)3.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
EPS Next Y20.21%
EPS Next 2Y19.5%
EPS Next 3Y18.59%
EPS Next 5Y5.77%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%
Revenue Next Year2.6%
Revenue Next 2Y4.84%
Revenue Next 3Y5.45%
Revenue Next 5Y-0.47%
EBIT growth 1Y14.22%
EBIT growth 3Y25.92%
EBIT growth 5Y22.25%
EBIT Next Year43.16%
EBIT Next 3Y20.98%
EBIT Next 5Y8.1%
FCF growth 1Y2.51%
FCF growth 3YN/A
FCF growth 5Y-6.32%
OCF growth 1Y15.21%
OCF growth 3Y73.5%
OCF growth 5Y-2.15%

AMNEAL PHARMACEUTICALS INC / AMRX Fundamental Analysis FAQ

What is the fundamental rating for AMRX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AMRX.


What is the valuation status for AMRX stock?

ChartMill assigns a valuation rating of 7 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.


Can you provide the profitability details for AMNEAL PHARMACEUTICALS INC?

AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for AMRX stock?

The Price/Earnings (PE) ratio for AMNEAL PHARMACEUTICALS INC (AMRX) is 14.93 and the Price/Book (PB) ratio is -56.51.


Can you provide the expected EPS growth for AMRX stock?

The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 20.21% in the next year.